Cargando…

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

PURPOSE: Metastatic esophagogastric cancer treatments after failure of second-line chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced gastric or gastroesophageal junction cancers. We assessed the safety and efficacy of nivol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janjigian, Yelena Y., Bendell, Johanna, Calvo, Emiliano, Kim, Joseph W., Ascierto, Paolo A., Sharma, Padmanee, Ott, Patrick A., Peltola, Katriina, Jaeger, Dirk, Evans, Jeffry, de Braud, Filippo, Chau, Ian, Harbison, Christopher T., Dorange, Cecile, Tschaika, Marina, Le, Dung T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2018
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161834/ https://www.ncbi.nlm.nih.gov/pubmed/30110194 http://dx.doi.org/10.1200/JCO.2017.76.6212

Ejemplares similares

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial
por: Sharma, Padmanee, et al.
Publicado: (2016)

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
por: Ready, Neal, et al.
Publicado: (2018)

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)
por: Sangro, Bruno, et al.
Publicado: (2023)

Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
por: Yau, Thomas, et al.
Publicado: (2023)

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920
por: Emamekhoo, Hamid, et al.
Publicado: (2021)

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
por: Weber, Jeffrey S., et al.
Publicado: (2023)

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
por: Owonikoko, Taofeek K., et al.
Publicado: (2021)

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients
por: O’Byrne, K.J., et al.
Publicado: (2022)

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
por: Motzer, Robert J, et al.
Publicado: (2022)

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
por: Taylor, Matthew, et al.
Publicado: (2015)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
por: Tawbi, Hussein A, et al.
Publicado: (2021)

Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics—CheckMate 908
por: Dunkel, Ira J, et al.
Publicado: (2023)

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
por: Larkin, James, et al.
Publicado: (2023)

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
por: Lebbé, Celeste, et al.
Publicado: (2019)

An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)
por: Hellmann, Matthew, et al.
Publicado: (2015)

Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial
por: Harrington, Kevin J., et al.
Publicado: (2023)

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial
por: Yau, Thomas, et al.
Publicado: (2020)

Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment‐Related Adverse Events From the CheckMate 040 Study
por: Julien, Karen, et al.
Publicado: (2020)

CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
por: Lee, Alexandria T M, et al.
Publicado: (2023)

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
por: George, Daniel J, et al.
Publicado: (2022)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
por: Marchetti, Paolo, et al.
Publicado: (2020)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up
por: Tomita, Yoshihiko, et al.
Publicado: (2019)

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)
por: Hodi, F. Stephen, et al.
Publicado: (2020)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
por: He, Jie, et al.
Publicado: (2023)

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
por: Brahmer, Julie R., et al.
Publicado: (2023)

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
por: Haddad, Robert I., et al.
Publicado: (2023)

Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial
por: Lin, Yan, et al.
Publicado: (2023)

Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study
por: Yokota, Kenji, et al.
Publicado: (2019)

First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1
por: Nishio, Makoto, et al.
Publicado: (2023)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
por: Ready, Neal, et al.
Publicado: (2019)

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
por: Albiges, Laurence, et al.
Publicado: (2020)

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
por: Tykodi, Scott S, et al.
Publicado: (2022)

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA
por: John, Thomas, et al.
Publicado: (2022)

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
por: Ready, Neal E, et al.
Publicado: (2023)

Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1
por: Nishio, Makoto, et al.
Publicado: (2023)

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
por: Tomita, Yoshihiko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ssedg12nnetmst2pos14j85pkk